Canada markets closed

Celltrion, Inc. (068270.KS)

KSE - KSE Delayed Price. Currency in KRW
Add to watchlist
187,000.00-4,500.00 (-2.35%)
At close: 03:30PM KST
Full screen
Previous Close191,500.00
Open193,300.00
Bid187,300.00 x 0
Ask187,400.00 x 0
Day's Range184,700.00 - 193,500.00
52 Week Range131,000.00 - 241,000.00
Volume529,601
Avg. Volume658,962
Market Cap38.681T
Beta (5Y Monthly)0.31
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield500.00 (0.26%)
Ex-Dividend DateDec 27, 2023
1y Target EstN/A
  • Thomson Reuters StreetEvents

    Q4 2023 Rani Therapeutics Holdings Inc Earnings Call

    Q4 2023 Rani Therapeutics Holdings Inc Earnings Call

  • Reuters

    Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US

    South Korea's Celltrion Healthcare has launched a copycat version to AbbVie Inc's Humira at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S. The biosimilar, Yuflyma, became available for sale in the U.S. on Sunday, the company said a day later. Yuflyma is listed at $6,576.50 per month compared to the current list price of Humira at $6,922 per carton and is available in two device types — auto-injector and pre-filled syringe options.